Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CCR1 | P32246 | 10/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4793703 | 1.00 | KMT2A (0.56) | KMT2AMAPK1CCR1PABPC1HRH2 | |
| SCHEMBL2374758 | 0.86 | KMT2A (0.68) | KMT2AMAPK1CCR1PABPC1HRH2 | |
| SCHEMBL2374766 | 0.86 | KMT2A (0.68) | KMT2AMAPK1CCR1PABPC1HRH2 | |
| SCHEMBL4775641 | 0.85 | CCR1 (0.56) | CCR1 | |
| SCHEMBL6162295 | 0.82 | KMT2A (0.58) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL6162303 | 0.82 | KMT2A (0.58) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL4699053 | 0.81 | KMT2A (0.53) | KMT2AMAPK1CCR1PABPC1HRH2 | |
| SCHEMBL4699544 | 0.80 | KMT2A (0.53) | KMT2AMAPK1CCR1PABPC1HRH2 | |
| SCHEMBL4793472 | 0.80 | CCR1 (0.47) | KMT2AMAPK1CCR1PABPC1HRH2 | |
| SCHEMBL5064576 | 0.80 | HRH2 (0.58) | KMT2AMAPK1PABPC1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | KMT2A 41/4885MAPK1 3876/4885CCR1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.